Bevacizumab for Advanced Gynecological Cancer

DU Wen-jing; DONG Xin-fang; LIU Da-jiang; YANG Yong-xiu

Abstract：As clinical researches for malignant tumors developing, molecular targeted therapy, following radical surgery, chemotherapy and radiotherapy, has become a novel and the 4th treatment for the advanced gynecological cancers. It also gathered more and more attention of cancer researchers due to its high level of specificity and abilities of enhance the effect of the anticancer, extension the survival period of patient. More and more attention has been attracted by molecular targeted therapy of anti VEGF antibody, and bevacizumab becomes the focus of attention. Bevacizumab is a monoclonal antibody that can specifically combine with VEGF, which is the key regulatory factor on the growth of tumor blood vessels. By the process mentioned above, bevacizumab can prevent VEGF from combining with its receptor, thus inhibit the formation of tumor blood vessels and achieve anticancer efficacy. At present, bevacizumab is acting as first-line medicine to treat ovarian cancer, recurrent or advanced metastatic cervical cancer, colorectal cancer, lung cancer and renal cell carcinoma which was approved by the Food and Drug Administration (FDA). Recently, treating advanced gynecological cancers with the use of bevacizumab, which is regarded as a novel therapeutic, becomes the focus of numerous studies. This paper reviews research progress in bevacizumab to treat advanced gynecological cancers.